 |
11 Diseases |  |
2 Trials |
|
2 Trials |  |
424 News |  |
| 1234» |
- || PD-L1.t-haNK / ImmunityBio, Anktiva (nogapendekin alfa inbakicept-pmln) / ImmunityBio
Trial completion date, Trial primary completion date, Metastases: QUILT-88: Combination Immunotherapy Plus Standard-of-Care Chemotherapy Versus Standard-of-Care Chemotherapy for the Treatment of Locally Advanced or Metastatic Pancreatic Cancer (clinicaltrials.gov) - Oct 18, 2024
P2, N=328, Active, not recruiting, Sponsor: ImmunityBio, Inc.
Trial completion date: Oct 2024 --> Oct 2025 | Trial primary completion date: Oct 2024 --> Oct 2025
- | PD-L1.t-haNK / ImmunityBio, Anktiva (nogapendekin alfa inbakicept-pmln) / ImmunityBio
Journal: Recurrent pancreatic cancer treated with N-803 and PD-L1 t-haNK followed by an EGFR-targeted nanocell drug conjugate. (Pubmed Central) - Oct 7, 2024
The epidermal growth factor receptor-targeted antibody-nanocell conjugate E-EDV-D682 provides tumor-targeted chemotherapy in the form of its anthracycline metabolite PNU159682 (nemorubicin) cargo and is currently being studied in combination with immunomodulatory EDVs delivering the adjuvant ?-galactosyl ceramide (GC)...Under the initial single-patient Investigational New Drug (spIND) protocol, the patient received N-803, PD-L1 t-haNK cells, and the albumin doxorubicin conjugate aldoxorubicin for ~27 months...Due to progression, a second spIND protocol was designed whereby the patient received E-EDV-D682 plus EDV-GC for more than 24 months, which resulted in stable disease and the patient's continued survival at the time this report was written. The patient's extended survival despite the dire prognosis associated with recurrent mPC points to the merits of this temporal combination regimen in overcoming immuno-chemo resistance with enhanced immune activity required for tumor response and extended survival.
- | Phase classification, Enrollment change, Trial termination: QUILT-3.080: NANT Pancreatic Cancer Vaccine (clinicaltrials.gov) - Aug 27, 2024
P1/2, N=3, Terminated, Sponsor: ImmunityBio, Inc.
The patient's extended survival despite the dire prognosis associated with recurrent mPC points to the merits of this temporal combination regimen in overcoming immuno-chemo resistance with enhanced immune activity required for tumor response and extended survival. Phase classification: P1b/2 --> P1/2 | N=173 --> 3 | Unknown status --> Terminated; Study halted prematurely and will not resume; participants are no longer being examined or receiving intervention
- || PD-L1.t-haNK / ImmunityBio, Anktiva (nogapendekin alfa inbakicept-pmln) / ImmunityBio
Trial primary completion date, Metastases: QUILT-88: Combination Immunotherapy Plus Standard-of-Care Chemotherapy Versus Standard-of-Care Chemotherapy for the Treatment of Locally Advanced or Metastatic Pancreatic Cancer (clinicaltrials.gov) - Aug 18, 2024
P2, N=328, Active, not recruiting, Sponsor: ImmunityBio, Inc.
Phase classification: P1b/2 --> P1/2 | N=173 --> 3 | Unknown status --> Terminated; Study halted prematurely and will not resume; participants are no longer being examined or receiving intervention Trial primary completion date: Jun 2024 --> Oct 2024
- || ProLindac (AP 5346) / Abeona Therap, milatuzumab-doxorubicin antibody-drug conjugate (hLL1-DOX) / Gilead, aldoxorubicin (INNO-206) / LadRx
Review, Journal: Acid-sensitive prodrugs; a promising approach for site-specific and targeted drug release. (Pubmed Central) - Aug 10, 2024
Trial primary completion date: Jun 2024 --> Oct 2024 These prodrugs include albumin-binding prodrugs (Aldoxorubicin and DK049), polymeric micelle (NC-6300), polymer conjugates (ProLindac
- | Enrollment change, Trial completion date, Trial termination: QUILT-3.067: NANT Triple Negative Breast Cancer (TNBC) Vaccine: Molecularly Informed Integrated Immunotherapy in Subjects With TNBC Who Have Progressed on or After Standard-of-care Therapy. (clinicaltrials.gov) - Aug 9, 2024
P1/2, N=9, Terminated, Sponsor: ImmunityBio, Inc.
These prodrugs include albumin-binding prodrugs (Aldoxorubicin and DK049), polymeric micelle (NC-6300), polymer conjugates (ProLindac N=79 --> 9 | Trial completion date: Oct 2023 --> Jan 2024 | Active, not recruiting --> Terminated; Study halted prematurely and will not resume; participants are no longer being examined or receiving intervention
- | Enrollment change, Trial termination: QUILT-3.090: NANT Squamous Cell Carcinoma (SCC) Vaccine: Subjects With SCC Who Have Progressed (clinicaltrials.gov) - Aug 5, 2024
P1/2, N=4, Terminated, Sponsor: ImmunityBio, Inc.
N=79 --> 9 | Trial completion date: Oct 2023 --> Jan 2024 | Active, not recruiting --> Terminated; Study halted prematurely and will not resume; participants are no longer being examined or receiving intervention N=65 --> 4 | Unknown status --> Terminated; Study halted prematurely and will not resume; participants are no longer being examined or receiving intervention
- ||| aldoxorubicin (INNO-206) / LadRx
Trial completion, Phase classification, Metastases: Efficacy and Safety of Aldoxorubicin Compared to Topotecan in Subjects With Metastatic Small Cell Lung Cancer (clinicaltrials.gov) - Jun 24, 2024
P2, N=135, Completed, Sponsor: ImmunityBio, Inc.
N=65 --> 4 | Unknown status --> Terminated; Study halted prematurely and will not resume; participants are no longer being examined or receiving intervention Unknown status --> Completed | Phase classification: P2b --> P2
- ||| aldoxorubicin (INNO-206) / LadRx
Trial completion, Phase classification, Metastases: Preliminary Efficacy and Safety of INNO-206 Compared to Doxorubicin in Advanced Soft Tissue Sarcoma (clinicaltrials.gov) - May 29, 2024
P2, N=126, Completed, Sponsor: ImmunityBio, Inc.
Unknown status --> Completed | Phase classification: P2b --> P2 Unknown status --> Completed | Phase classification: P2b --> P2
- | Enrollment change, Trial termination: QUILT-3.070:Pancreatic Cancer Vaccine: Subjects With Pancreatic Cancer Who Have Progressed on or After Standard-of-care Therapy (clinicaltrials.gov) - May 22, 2024
P1/2, N=4, Terminated, Sponsor: ImmunityBio, Inc.
Unknown status --> Completed | Phase classification: P2b --> P2 N=173 --> 4 | Unknown status --> Terminated; Study halted prematurely and will not resume; participants are no longer being examined or receiving intervention
- ||| PD-L1.t-haNK / ImmunityBio, Anktiva (nogapendekin alfa inbakicept-pmln) / ImmunityBio
Enrollment closed, Metastases: QUILT-88: Combination Immunotherapy Plus Standard-of-Care Chemotherapy Versus Standard-of-Care Chemotherapy for the Treatment of Locally Advanced or Metastatic Pancreatic Cancer (clinicaltrials.gov) - Jan 18, 2024
P2, N=328, Active, not recruiting, Sponsor: ImmunityBio, Inc.
N=173 --> 4 | Unknown status --> Terminated; Study halted prematurely and will not resume; participants are no longer being examined or receiving intervention Recruiting --> Active, not recruiting
- || Trial completion date, Trial primary completion date: QUILT-3.067: NANT Triple Negative Breast Cancer (TNBC) Vaccine: Molecularly Informed Integrated Immunotherapy in Subjects With TNBC Who Have Progressed on or After Standard-of-care Therapy. (clinicaltrials.gov) - Sep 28, 2023
P1/2, N=79, Active, not recruiting, Sponsor: ImmunityBio, Inc.
Recruiting --> Active, not recruiting Trial completion date: Jan 2023 --> Oct 2023 | Trial primary completion date: Dec 2022 --> Sep 2023
- | aldoxorubicin (INNO-206) / ImmunityBio
Journal: Physalis Mottle Virus-Like Nanocarriers with Expanded Internal Loading Capacity. (Pubmed Central) - Aug 24, 2023
Specifically, the A31C and S137C mutants show a greater than 10-fold increased rate of reactivity towards thiol-reactive small molecules, and PhMV Cys1 (A31C), PhMV Cys2 (S137C), and PhMV Cys1+2 (double mutant) VLPs display up to three-fold increased internal loading of the small molecule chemotherapeutics aldoxorubicin and vcMMAE and up to four-fold increased internal loading of the MRI imaging reagent DOTA(Gd). These results further improve upon a promising plant virus-based nanocarrier system for use in targeted delivery of small-molecule drugs and imaging reagents in vivo.
- aldoxorubicin (INNO-206) / ImmunityBio, Anktiva (inbakicept) / ImmunityBio
Overall survival in patients with metastatic or locally advanced pancreatic cancer following chemoradiation with novel combination of aldoxorubicin, N-803 IL-15 superagonist, and PDL1- NK cell therapy. (Available On Demand; Poster Board No. L7) - Dec 13, 2022 - Abstract #ASCOGI2023ASCO_GI_577;
P2
A doubling of survival in 3rd line is seen in QUILT 88 investigating a novel combination immunotherapy protocol of low-dose chemoradiation, N-803 and PDL1 t-haNK therapy. Updated data will be presented.
- | aldoxorubicin (INNO-206) / ImmunityBio
Journal: Supramolecular Organic Frameworks: Exploring Water-Soluble, Regular Nanopores for Biomedical Applications. (Pubmed Central) - Aug 22, 2022
As new supramolecular drugs and carriers, dSOFs are generally biocompatible. Thus, further efforts might lead to medical benefits in the future.
- | doxorubicin hydrochloride / Generic mfg.
Journal: Targeted Drug Delivery Biopolymers Effectively Inhibit Breast Tumor Growth and Prevent Doxorubicin-Induced Cardiotoxicity. (Pubmed Central) - Jun 19, 2022
SynB1-ELP1-DOXO biopolymers demonstrated a 6-fold increase in tumor/heart ratio in comparison to free doxorubicin, indicating preferential accumulation of the drug in tumors. These results demonstrate that thermally targeted polymers are a promising therapy to enhance tumor targeting and uptake of anticancer drugs and to minimize free drug toxicity in healthy tissues, representing a great potential for clinical application.
- | aldoxorubicin (INNO-206) / ImmunityBio
Journal: Conjugating aldoxorubicin to supramolecular organic frameworks: polymeric prodrugs with enhanced therapeutic efficacy and safety. (Pubmed Central) - Jun 11, 2022
Moreover, the SOF prodrugs do not show cardiotoxicity, the major superiority of AlDox over Dox. Since free AlDox is conjugated to endogenous albumin in the blood through thiol-maleimide addition to achieve enhanced intracellular delivery and Dox release through acid-responsive hydrazone hydrolysis, SOF conjugation provides a surrogate strategy for prodrug design to gain improved efficacy.
- Anktiva (inbakicept) / ImmunityBio
Phase 2 Quilt 88 trial of DAMP inducers combined with IL15 superagonist, N-803, and anti–PD-L1 NK cell therapy more than doubles historical overall survival in patients with third- to sixth-line advanced pancreatic cancer. (Available On Demand; 132) - Apr 28, 2022 - Abstract #ASCO2022ASCO_1983;
P2
Early safety and efficacy is seen in QUILT 88 of the novel immunotherapy combination of DAMP inducers, NK and T cell activation, and PDL1 t-haNK cell therapy in Pancreatic Cancer. OS in 3rd line (6.3 months) exceeds historical results of 3 months across 19 trials (Manax ASCO GI 2019) and compares favorably with the 6.1 months in 2nd line patients in NAPOLI-1.
- | doxorubicin hydrochloride / Generic mfg.
Journal: Enhanced Antitumor Efficacy of PhAc-ALGP-Dox, an Enzyme-Activated Doxorubicin Prodrug, in a Panel of THOP1-Expressing Patient-Derived Xenografts of Soft Tissue Sarcoma. (Pubmed Central) - Apr 24, 2022
For both experimental prodrugs, strong immunostaining for THOP1 was found to predict better antitumor efficacy. The prodrugs were well tolerated without any adverse events, even though molar doses were 17-fold higher than those administered and tolerated for doxo.
- || Trial completion date, Trial primary completion date: QUILT-3.067: NANT Triple Negative Breast Cancer (TNBC) Vaccine: Molecularly Informed Integrated Immunotherapy in Subjects With TNBC Who Have Progressed on or After Standard-of-care Therapy. (clinicaltrials.gov) - Mar 29, 2022
P1/2, N=79, Active, not recruiting, Sponsor: ImmunityBio, Inc.
The prodrugs were well tolerated without any adverse events, even though molar doses were 17-fold higher than those administered and tolerated for doxo. Trial completion date: Jan 2020 --> Jan 2023 | Trial primary completion date: Dec 2019 --> Dec 2022
- || Trial completion date, Trial primary completion date, Metastases: QUILT-3.071: QUILT 3.071: NANT Colorectal Cancer (CRC) Vaccine (clinicaltrials.gov) - Mar 29, 2022
P1b/2, N=332, Active, not recruiting, Sponsor: ImmunityBio, Inc.
Trial completion date: Jan 2020 --> Jan 2023 | Trial primary completion date: Dec 2019 --> Dec 2022 Trial completion date: Dec 2021 --> Dec 2022 | Trial primary completion date: Dec 2021 --> Dec 2022
- aldoxorubicin (INNO-206) / LadRx
Phase classification, Metastases: Phase 1b Study to Investigate the Safety and Maximum Tolerated Dose of Aldoxorubicin (INNO-206) Plus Doxorubicin HCL in Subjects With Advanced Solid Tumors (clinicaltrials.gov) - Feb 10, 2022
P1b, N=15, Completed, Sponsor: ImmunityBio, Inc.
Trial completion date: Dec 2021 --> Dec 2022 | Trial primary completion date: Dec 2021 --> Dec 2022 Phase classification: P1 --> P1b
- ||| aldoxorubicin (INNO-206) / LadRx
Trial completion, Metastases: Study to Investigate the Safety and Activity of Aldoxorubicin Plus Ifosfamide/Mesna in Subjects With Metastatic Soft Tissue Sarcoma (clinicaltrials.gov) - Feb 10, 2022
P1/2, N=70, Completed, Sponsor: ImmunityBio, Inc.
Phase classification: P1 --> P1b Recruiting --> Completed
- | cisplatin / Generic mfg., epirubicin / Generic mfg.
Retrospective data, Journal: Comparison of first line chemotherapy regimens for advanced soft tissue sarcoma: a network meta-analysis. (Pubmed Central) - Feb 4, 2022
No regimen was superior to doxorubicin with significant statistical difference in terms of PFS and ORR, even aldoxorubicin behaved better than doxorubicin in the network analysis. Collectively, doxorubicin still can be selected preferentially for the first line chemotherapy for patients.
- || aldoxorubicin (INNO-206) / ImmunityBio
@SenWarren @SenMarkey @SenSchumer $CYTR s drug Aldoxorubicin was used to treat Senator Harry Reid @SenateDems @drallysonocean @60minutes https://t.co/nXoMTBQmrQ (Twitter) - Jan 23, 2022
- ||| aldoxorubicin (INNO-206) / ImmunityBio
Clinical: @DrPatSoonShiong why did you prevent Aldoxorubicin from getting to cancer patients? 2017 2018 2019 2020 2021 2022 ? Why? @davidfaber @MorganLBrennan @SenWarren @FDAOncology (Twitter) - Jan 23, 2022
- |||| aldoxorubicin (INNO-206) / ImmunityBio
NDA: @DrPatSoonShiong file the NDA for Aldoxorubicin Patrick + get on the right team @KIDSvCANCER https://t.co/FngxOURLpA @davidfaber @megtirrell @MorganLBrennan @CNBC @FDAOncology @DanaFarber @MGHCancerCenter @WSJ @60Minutes @hoaghealth @JohnCendpts @cher @OncJournal @AdamSandler (Twitter) - Jan 17, 2022
- aldoxorubicin (INNO-206) / ImmunityBio, Anktiva (inbakicept) / ImmunityBio
Promising survival and disease control in third-line or greater metastatic or locally advanced pancreatic cancer patients following chemo-radiation and novel combination of aldoxorubicin, N-803 IL-15 superagonist, and PDL1- NK cell therapy. (In-Person Only | Level 1, West Hall; Poster Board - J10) - Jan 8, 2022 - Abstract #ASCOGI2022ASCO_GI_836;
P2
Early safety and promising efficacy is seen in QUILT 88 investigating a novel combination immunotherapy protocol of low-dose chemoradiation, N-803 and PDL1 t-haNK therapy. Updated data will be presented.
- ||||| aldoxorubicin (INNO-206) / ImmunityBio
@DrPatSoonShiong Congratulations to Inventor Pat Soon Shiong! Bravo!!! Inventor of Aldoxorubicin @SenWarren @SenMarkey patent included below: ! https://t.co/FngxOURLpA @FLOTUS @MarcoLDavila @NiraliShahMD @ASH_hematology @fredhutch @sloan_kettering @davidfaber @60Minutes @nytimes (Twitter) - Dec 21, 2021
- ||| PD-L1.t-haNK / ImmunityBio, Anktiva (nogapendekin alfa inbakicept-pmln) / ImmunityBio
Enrollment change, Metastases: QUILT-88: Combination Immunotherapy Plus Standard-of-Care Chemotherapy Versus Standard-of-Care Chemotherapy for the Treatment of Locally Advanced or Metastatic Pancreatic Cancer (clinicaltrials.gov) - Oct 18, 2021
P2, N=328, Recruiting, Sponsor: ImmunityBio, Inc.
Updated data will be presented. N=248 --> 328
- | aldoxorubicin (INNO-206) / ImmunityBio
Journal: Self-Activatable Photo-Extracellular Vesicle for Synergistic Trimodal Anticancer Therapy. (Pubmed Central) - Oct 16, 2021
M1 macrophage-derived EVs (M1 EVs) are simultaneously loaded with bis[2,4,5-trichloro-6-(pentyloxycarbonyl) phenyl] oxalate (CPPO), chlorin e6 (Ce6), and prodrug aldoxorubicin (Dox-EMCH)...Meanwhile, O -induced membrane rupture leads to the release of Dox-EMCH, which is then activated and penetrates the deep hypoxic areas of tumors. The synergism of immunotherapy, PDT, and chemotherapy results in potent anticancer efficacy, showing great promise to fight cancers.
- || PD-L1.t-haNK / ImmunityBio, Anktiva (nogapendekin alfa inbakicept-pmln) / ImmunityBio
Trial completion date, Trial primary completion date, Metastases: QUILT-88: Combination Immunotherapy Plus Standard-of-Care Chemotherapy Versus Standard-of-Care Chemotherapy for the Treatment of Locally Advanced or Metastatic Pancreatic Cancer (clinicaltrials.gov) - Sep 5, 2021
P2, N=248, Recruiting, Sponsor: ImmunityBio, Inc.
The synergism of immunotherapy, PDT, and chemotherapy results in potent anticancer efficacy, showing great promise to fight cancers. Trial completion date: Jun 2022 --> Sep 2024 | Trial primary completion date: Jun 2021 --> Jun 2024
- | aldoxorubicin (INNO-206) / ImmunityBio
Journal: Improving Bioavailaibity of Hydrophobic Prodrugs through Supramolecular Nanocarriers based on Recombinant Proteins for Osteosarcoma Treatment. (Pubmed Central) - Aug 11, 2021
Here, we developed a new generation of recombinant protein-based nanodrug carriers, which is very efficient for loading and delivering the hydrophobic prodrug aldoxorubicin...Importantly, off-target side effects of the prodrug including cardiotoxicity and lung-metastasis were greatly mitigated with our medication. Thus, our assembly strategy potently enables customized designs of advanced nanodelivery systems employing broader biomaterial building blocks for cancer therapy.
- |||| aldoxorubicin (INNO-206) / ImmunityBio, Cynviloq (paclitaxel polymeric micelle formulation) / Sorrento, Samyang Group, ImmunityBio, Abraxane (albumin-bound paclitaxel) / BMS, Otsuka
Corporate lawsuit: @DrPatSoonShiong it is hard to estimate what is better a) protecting Abraxane sales while blocking, delaying, shelving Cynviloq, Aldoxorubicin or b) going through multiple lawsuits of fraudulent concealment (Twitter) - Aug 3, 2021
- ||| aldoxorubicin (INNO-206) / ImmunityBio
Interview: @DrPatSoonShiong had numerous public interviews and not once did he mention Aldoxorubicin is dosing 40 x FDA restriction of dox. @megtirrell @RiggsReport @davidfaber @MorganLBrennan Soon Shiong lied blatantly lied. Ask him why his name is on the Aldoxorubicin patent (Twitter) - Aug 3, 2021
- ||| aldoxorubicin (INNO-206) / ImmunityBio
$CYTR $IBRX $SRNE $ORPH Inventor John H. Lee + Patrick Soon-Shiong @DrPatSoonShiong [Remarkably, the inventors did not find any evidence of cardiac toxicity of aldoxorubicin up to doxorubicin equivalent doses of 7,500 mg/m] @AACR @AmericanCancer @KIDSvCANCER @MorganLBrennan @cnbc (Twitter) - Jul 28, 2021
- ||| aldoxorubicin (INNO-206) / ImmunityBio, Cynviloq (paclitaxel polymeric micelle formulation) / Sorrento, Samyang Group, ImmunityBio
NDA: @NEJM @BarackObama @latimes @KingJames @CDCgov @megtirrell @LakersReporter @pcvblack @RickABright @cselecky @EdHammondNY @cher Dr. @DrPatSoonShiong preventing Aldoxorubicin + Cynviloq from going to market [acquired during non compete] June 2010 to June 2020 failing to file NDA (Twitter) - Jul 27, 2021
- ||| aldoxorubicin (INNO-206) / ImmunityBio
Clinical, NDA: Patent Covers the Formulation, Storage, Delivery and Administration of Aldoxorubicin at Room Temperature Eliminates Need for Cold Handling new Improved Patent & Formula and @DrPatSoonShiong still fails to file NDA @SenWarren @FDA_Drug_Info @FDAOncology @hoaghealth @JohnCendpts (Twitter) - Jul 17, 2021
- ||| aldoxorubicin (INNO-206) / ImmunityBio
Clinical: Aldoxorubicin helped Alex trabec and senator Harry Reid but @DrPatSoonShiong has the drug hidden. 💰💰💰💰Profits over people!! Total scumbag 🙏🏻🙏🏻 (Twitter) - Jul 15, 2021
- || aldoxorubicin (INNO-206) / ImmunityBio
Aldoxorubicin https://t.co/FngxOURLpA (Twitter) - Jul 14, 2021
- | aldoxorubicin (INNO-206) / ImmunityBio
did they file the new drug app for aldoxorubicin? @DrPatSoonShiong has had rights to aldox since 2017 (Twitter) - Jul 7, 2021
- || aldoxorubicin (INNO-206) / ImmunityBio
Aldoxorubicin?!! (Twitter) - Jul 7, 2021
- || aldoxorubicin (INNO-206) / ImmunityBio
check out who has his name on the patent for Aldoxorubicin now https://t.co/FngxOURLpA none other than @DrPatSoonShiong the world's richest doctor - who at this point needs to buy out $CYTR (Twitter) - Jun 18, 2021
- || aldoxorubicin (INNO-206) / ImmunityBio
this is probably the most interesting find because @DrPatSoonShiong 🤏🤏 is holding his name on the Aldoxorubicin patent now 4 years later https://t.co/FngxOURLpA (Twitter) - Jun 18, 2021
- |||| aldoxorubicin (INNO-206) / ImmunityBio
question $CYTR's Aldoxorubicin = if it is a superior Albumin Binding nab synthetic anthracycline immunomodulator - why did @DrPatSoonShiong hide it in a private company he created - then took it public when the non compete agreement ended w Celgene?@RiggsReport @davidfaber (Twitter) - Jun 14, 2021
- |||| aldoxorubicin (INNO-206) / ImmunityBio
Clinical: my understanding is @DrPatSoonShiong is testing in South Africa: Immunity Bio $IBRX is also using $CYTR's Aldoxorubicin in cancer clinical trials with good effect. https://t.co/ABFGGBGKUw (Twitter) - Jun 12, 2021
- | aldoxorubicin (INNO-206) / ImmunityBio
why isnt aldoxorubicin discussed in public? come on give 1 reasonable answer (Twitter) - Jun 10, 2021
- |||| aldoxorubicin (INNO-206) / ImmunityBio
Clinical: you think you can come to Boston MGH with dying cancer patients, steal a drug, then hide it 4 years so it shows up in your $IBRX trials @DrPatSoonShiong? $CYTR owns Aldoxorubicin @AdamSandler @davidfaber @hismailosman @tmprowell @jimcramer @TheRoaringKitty @stoolpresidente @cher (Twitter) - Jun 8, 2021
- ||| aldoxorubicin (INNO-206) / ImmunityBio
Congratulations to @Lakers billionaire @DrPatSoonShiong for discovering $CYTR's Aldoxorubicin does not cause cardio toxicity @HalaBorno @OncoAlert #ASCO2021 @ASCO @NarjustDumaMD @neerajaiims @TiansterZhang @montypal @DrChoueiri @ucla @harvardmed https://t.co/FngxOURLpA (Twitter) - Jun 8, 2021
- |||| aldoxorubicin (INNO-206) / ImmunityBio
don't forget to read @DrPatSoonShiong's patent for Aldoxorubicin an Albumin binding synthetic immunomodulator anthracycline- that is the less cardiotoxic version of doxorubicin https://t.co/FngxOURLpA (Twitter) - Jun 5, 2021